AstraZeneca To Partner With Quell In Buzzing Treg Field
Company Joins Peers In Investing In Regulatory T Cells
AstraZeneca has paid $85m upfront to develop Tregs against two autoimmune conditions, type 1 diabetes and inflammatory bowel disease
You may also be interested in...
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001 which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."
The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.